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Abstract 
Aim: We investigated the effect of early-life factors, namely sex, delivery mode, feeding 
method and antibiotic exposure, on antibody responses to routine vaccinations administered 
during the first year of life.  
Methods: One and seven months after the primary course of routine vaccines and one month 
after routine vaccines at 12 months of age, antibodies against 26 vaccine antigens were 
measured in 398 healthy infants. The geometric mean concentration (GMC) of antibodies 
(adjusted for effect modifiers with multiple linear regression) and the seroprotection rate for 
each vaccine were compared for each early-life factor.  
Results: Sex had an influence on GMCs. Antibody concentrations were significantly lower at 
7 months of age in females for tetanus and filamentous haemagglutinin and at 13 months of 
age for pertactin. In contrast, at 13 months of age, antibody concentrations were significantly 
higher in females for polio type 3, pneumococccal serotype 6A and measles. Sex did not have 
an influence on seroprotection rates. Delivery mode, feeding method and antibiotic exposure 
did not exert a substantial influence on vaccine antibody concentrations. 
Conclusion: There is a difference between males and females in the humoral response to 
routine vaccinations in the first year of life.   
4 
 
Key Notes 
• There are substantial differences between individuals in the immune response to 
vaccination. 
• In this study, we found that there are differences between males and females in 
antibody responses to routine vaccinations in the first year of life. 
• In contrast, delivery mode, feeding method and antibiotic exposure does not affect 
antibody responses.  
 
Keywords: antibodies, humoral, immunoglobulin, titre, immunisation, infant 
 
  
5 
 
Introduction 
Vaccination is one of the most cost-effective, life-saving medical interventions. However, 
there is substantial variation between individuals in the magnitude of the immune response to 
vaccination, which might have implications for both protective efficacy and duration of 
protection. At the age of six months, for example, antibody responses to pneumococcal and 
Haemophilus influenzae type b (Hib) vaccines may vary up to 40-fold (1).  
A number of intrinsic host, perinatal and extrinsic factors are likely to contribute to the 
variation in vaccine responses (2). One of the intrinsic factors that has been most investigated 
is biological sex. But studies to date have almost exclusively been in adults. Other intrinsic 
factors include polymorphisms in genes encoding major histocompatibility complexes or 
pattern recognition receptors, such as Toll-like or RIG-like receptors (2). Perinatal factors that 
might influence vaccine responses include gestational age, birth weight (3, 4) and feeding 
method (formula vs breastfed). Potential extrinsic factors include exposure to probiotics and 
antibiotics. While, there is evidence for a beneficial effect of probiotics on vaccine responses 
(2), to date, only one study has investigated the effect of antibiotics in vaccine responses in 
humans. This study reported that administration of antibiotics before vaccination did not alter 
serum immunoglobulin (Ig) A concentrations to oral rotavirus vaccine (ORV) in adults (5). 
Determining the influence of intrinsic and extrinsic factors on vaccine antibody responses has 
implications for optimising vaccine recommendations and individualising vaccine schedules.  
In this study, we investigated the effect of biological sex, mode of delivery, feeding method 
and antibiotic exposure on antibody responses to routine vaccinations given in the first year of 
life.  
 
Methods 
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Study design and population 
Participants were a subset of 471 healthy infants from The Melbourne Infant Study: Bacille 
Calmette-Guérin (BCG) for Allergy and Infection Reduction (MIS BAIR) (http://misbair.org). 
In this trial infants were recruited at birth from 2013 to 2016 and randomised to receive 
neonatal BCG vaccination or no intervention to investigate whether BCG protects from 
childhood allergies. Inclusion criteria included the following: greater than 32 weeks gestation 
and birth weight greater than 1500 grams. Details about feeding and antibiotic exposure were 
prospectively collected by parent questionnaire. 
From the subset of participants whose parent/guardian provided consent, blood samples were 
collected at study visits at 7 and / or 13 months of age (designed to be 4 weeks after the 
administration of routine scheduled vaccinations). Only participants who had a blood taken 28 
± 14 days after their 6-month and / or 12-month routine vaccinations were included in the 
analysis of immediate post-vaccination responses. For those in whom persistence of 
antibodies to their 6-month vaccines was measured blood was taken 7 months ± 23 days after 
their 6-month vaccinations. 
 
Infant vaccination 
All infants received routine vaccinations according to the Australian National Immunisation 
Program: at birth: intramuscular hepatitis B (HepB) vaccine (H-B-Vax II Paediatric®, 
bioCSL)); at 6 weeks, 4 months and 6 months of age: intramuscular combined diphtheria-
tetanus-acellular pertussis (DTPa)-HepB-inactivated polio (IPV)-Hib vaccine (Infanrix® Hexa 
(GlaxoSmithKline)), intramuscular conjugate pneumococcal vaccine (PCV13) (Prevenar13® 
(Wyeth)) and ORV (RotaTeq® (Merck)); at 12 months of age: subcutaneous measles-mumps-
rubella (MMR) vaccine (Priorix® (GlaxoSmithKline)) and intramuscular combined Hib and 
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conjugated meningococcal C vaccine (Menitorix® (GlaxoSmithKline)). Approximately half of 
the infants received intradermal BCG-Denmark (Statens Serum Institut, Copenhagen) shortly 
after birth as part of the MIS BAIR. Vaccine records were obtained from individual 
vaccination records and/or the Australian Immunisation Register. 
 
Blood collection and antibody assay 
Following collection (S-monovette® (Sarstedt)), plasma was stored at -80° C until analysis at 
the National Institute for Health and Environment, in Bilthoven, the Netherlands. IgG 
antibodies against 26 vaccine antigens (diphtheria, tetanus, pertussis (pertussis toxin (PT), 
filamentous haemagglutinin (FHA), pertactin (PRN)), polio (types 1, 2, 3), Hib, 
pneumococcus (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F], meningococcus 
type C (MenC), measles, mumps and rubella) were measured using fluorescent bead-based 
multiplex immune-assays (Luminex xMAP technology). In all assays, international or in-
house reference controls and blanks were included on each plate. All analyses were performed 
with a Bio-Plex 200 in combination with Bio-Plex manager software (Bio-Rad Laboratories, 
Hercules, CA). 
 
Categorisation of participants 
Infants were categorised by biological sex (male or female), delivery mode (vaginal vs 
Caesarean section), feeding method and antibiotic exposure using information collected from 
hospital records and parent questionnaires. Feeding method was categorised as follows: i) 
infants who did or did not receive formula before leaving their birth hospital; ii) infants who 
were or were not still receiving breast milk at one month of age; iii) infants who were or were 
not still receiving breast milk at six months of age. Antibiotic exposure was categorised as 
follows: i) infants whose mother did or did not receive antibiotics during delivery; ii) infants 
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who did or did not received systemic antibiotics before their first routine vaccinations 
scheduled at the age of six weeks (assessed individually). 
 
Statistical analysis 
In each group, the proportion of infants with an antibody concentration above the standard 
protective correlate value (seroprotection rate) was calculated for each vaccine.(6-8) The 
Clopper-Pearson method was used to estimate the 95% confidence intervals (CIs) of the 
seroprotection rates. The rates were compared between groups using Fisher’s exact test and 
the 95% confidence interval (CI) for differences in proportions estimated. For FHA and PRN, 
no standard protective correlate value exists. In each group, the geometric mean concentration 
(GMC) for each vaccine antibody was calculated. The geometric mean ratio (GMR) with 95% 
confidence interval (CI) was obtained as the anti-logged coefficient from a linear regression 
with log-concentrations as outcome and early-life factors (biological sex, delivery mode, 
feeding choice and antibiotic exposure) as covariates (univariate regression). Effect 
modification was assessed using multiple linear regression with the following pre-specified 
factors: maternal age, maternal diphtheria-tetanus-pertussis (dTpa, Boostrix® 
(GlaxoSmithKline)) and trivalent influenza vaccination in pregnancy, birth weight, gestational 
age, infant BCG and MMR vaccination status, age at first DTPa-HepB-IPV-Hib / PCV13 
vaccination, age at sampling and time interval between 6-month or 12-month vaccination and 
blood sampling. The GMR for each vaccine antigen was adjusted for those factors that had an 
effect on vaccine antigen response. As the Hib-MenC vaccine includes a tetanus toxoid (as 
carrier protein) and a Hib component, infants who had received this vaccine before blood 
sampling at 13 months of age were excluded from the analysis of persistence of antibodies 
against these two vaccine antigens. A 5%-significance level was used. All statistical analyses 
were done using R version 3.4.3. 
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Ethics 
Informed consent was obtained from participants’ parents or guardians. The study was 
approved by the Royal Children’s Hospital Human Research Ethics Committee (HREC, 
authorisation, 38124A). 
 
Results 
Of the 471 participants, seven were excluded because they were a twin of another participant, 
five because extended parental consent to use the blood samples was not available, four 
because they were not vaccinated according to the routine schedule and one because vaccine 
records were not available (Figure 1). Of the remaining 454 participants, 365 had blood taken 
in the predefined time frame. At 7 months of age, 91 were included in the final analysis. At 13 
months of age, 307 were included for measurement of persistence of antibodies against the 
primary course of vaccines ending at 6 months and 141 for antibody responses to the 12-
month vaccines. The background characteristics of the 365 included participants are 
summarised in Table 1. The median gestational age was 39.3 weeks (interquartile range (IQR) 
38.4-40.4) and the median birth weight 3.45 kg (IQR 3.13-3.76). 
Of the 365 infants, 179 (49%) were male, 137 (37%) were born by Caesarean section and 100 
(28%) had received formula milk before discharge from their birth hospital. At 1 month of 
age, 302 (83%) infants were still receiving breast milk, at 6 months of age this number was 
263 (72%). In total, 70 (19%) mothers received antibiotics during delivery: 36 (51%) because 
they were colonised with group B streptococcus, 27 (39%) because of prolonged rupture of 
membranes, 5 (7%) because of Caesarean section delivery and for 2 (3%) the reason was not 
specified. The administered antibiotics were benzylpenicillin (n=30), amoxycillin (n=14), 
ampicillin (n=11), cephazolin (n=5), cefotaxime (n=1), metronidazole (n=1) and not specified 
(n=11).  
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Antibiotics were administered to 30 (8%) infants before their first routine vaccination 
schedule at six weeks of life. These infants received only one course of antibiotics each. The 
majority (n=22, 73%) received antibiotics within the first week of life (intravenous 
benzylpenicillin and gentamicin (n=18), intravenous benzylpenicillin, gentamicin and 
vancomycin (n=1), intravenous antibiotics not documented (n=1), oral cephalexin (n=1), and 
oral flucloxacillin (n=1)). The duration of administration varied between 2 and 7 days (mean 
3, median 3). Of the remaining 8 infants, 4 were admitted to hospital for intravenous 
antibiotics (azithromycin (n=1) and antibiotics not documented (n=3)) between 2 and 5 weeks 
of age (mean 3.5, median 3.5). The duration of administration was less than 5 days (n=2 
infants) and between 5 and 10 days (n=2 infants). The infant who received intravenous 
azithromycin was continued on oral azithromycin for 3 days. Additionally, two infants were 
continued on oral antibiotics (not documented), one for 5 days and one for more than 10 days. 
There were 4 infants who received oral antibiotics after the first week of life (age range 2 to 4, 
mean 3.8, median 4 weeks) (amoxicillin (n=2), cephalexin (n=2)). The duration of 
administration was 5 to 10 days for all. 
 
Sex influences the magnitude of responses to certain vaccines 
At 7 months of age, females had a lower seroprotection rate against Hib compared with male 
infants (66% (95% CI 51.6-79.6%) vs 86% (95% CI 72.1-94.7%); p=0.05). However, overall 
there were no statistically significant differences between males and females in seroprotection 
rates at 7 or 13 months of age (Table 2a and Figure 2). After adjustment for pre-specified 
factors, the female:male GMR was below one (indicating lower average antibody 
concentrations) in females for tetanus and FHA (Table 2b and Figure 2) at 7 months of age 
and for PRN at 13 months of age. These findings were statistically significant. At 13 months 
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of age, adjusted average antibody concentrations were statistically significantly higher in 
females for polio type 3, pneumococcus serotype 6A and measles (Table 2b and Figure 2). 
 
No effect of delivery mode on vaccine responses 
At 7 months of age, seroprotection rates were lower in infants born vaginally than in those 
born by Caesarean section for the majority of vaccine antigens. However, none of these 
differences reached statistical significance. At 13 months of age, there were no differences in 
seroprotection rates between infants born vaginally or by Caesarean section (Supplementary 
Table S1a and Figure S1). At 13 months of age, infants born vaginally had a higher average 
antibody concentration against Hib (Supplementary Table S1b and Figure S1). 
 
No effect of feeding method on vaccine antibody responses 
At 7 and 13 months of age, there were no statistically significant differences in seroprotection 
rates or adjusted average antibody concentrations between infants who received or did not 
receive formula milk in first few days of life or between infants who were still receiving 
breast milk at 1 or 6 months of age and those who were not (Supplementary Tables S2a-4b 
and Figures S2-4). The only exception was a statistically significant higher adjusted average 
antibody concentration (i.e. a GMR greater than one) against pneumococcus serotype 7F at 7 
months of age in infants who did not receive formula milk during the first few days of life 
compared to those who did (Supplementary Table S2b and Figure S2), and higher antibody 
concentration for pneumococcus serotype 19F and MenC at 13 months of age in infants who 
were still receiving breast at 6 months of age (Supplementary Tables S4b and Figure S4). 
 
Minimal effect of intrapartum or infant antibiotic exposure on vaccine responses 
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At 7 and 13 months of age, there were no differences in seroprotection rates between infants 
whose mothers did or did not receive antibiotics during delivery (Supplementary Table S5a 
and Figure S5). Infants whose mother received intrapartum antibiotics had a significantly 
higher adjusted average antibody concentration against PRN at 7 months and 13 months of 
age of age (Supplementary Tables S5b and Figure S5). Antibiotic exposure before their first 
routine vaccination scheduled at 6 weeks of age did not influence seroprotection rates or 
average antibody concentrations (Supplementary Table S6a-6b and Figure S6). 
 
Discussion 
This study is the first to investigate the effect of multiple different early-life factors on 
antibody responses to routine vaccinations in infancy. We found that infant biological sex had 
an impact on responses but delivery mode, feeding method, intrapartum antibiotics, and 
antibiotic exposure before the first routine immunisation did not.  
Our finding that females had lower antibody responses against tetanus, and higher responses 
against polio (type 3) is consistent with previous studies in adults (9-11). Previous studies 
have also reported female adults to have higher antibody responses to dengue, HepA, HepB, 
rabies, smallpox, and trivalent influenza vaccines, while male adults have been reported to 
have higher responses to diphtheria, and conjugated meningococcus A vaccines (2). The only 
studies which have previously been done in infants, reported higher antibody responses in 
females to HepB, Hib  and PCV13 (2). Aside from a higher average antibody concentration in 
females against one pneumococcal serotype (6A), we did not find sex differences in the 
response to pneumococcal vaccination. This contrasts with studies in adults, in which males 
have generally been reported to have higher antibody responses to pneumococcal vaccines 
(2). 
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In our study, we found that female infants had higher antibody levels against measles at 13 
months of age than corresponding males. Previous studies investigating sex differences in 
responses to MMR vaccination report inconsistent findings. Some studies found higher 
antibody responses to measles, mumps, and rubella vaccination in females, whilst others 
found transiently lower GMCs to rubella and lower seroconversion rates to measles 
vaccination in females (2). Other studies did not find any sex differences in antibody 
responses to mumps and rubella, rubella vaccination. Notably, even though females are often 
reported to have higher antibody responses, faster waning of antibodies has been observed for 
antibodies against HepA and pneumococcus in females (2).  
One mechanisms through which sex can affect vaccine responses is through hormones: 
oestradiol, progesterone and testosterone all influence the function of immune cells (12). 
However, as sex differences in vaccine responses also occur before puberty and after 
menopause, other factors might also be involved. Many genes for proteins involved in the 
immune responses are encoded on the X chromosome, and mutations and polymorphisms of  
X-linked genes therefore have a greater impact in males (13). A further mechanism through 
which sex differences in vaccine responses might occur, is through epigenetic programming, 
which is also influenced by sex hormones (12).  
The microbiota, especially the intestinal microbiota, plays a crucial rule in the development 
and regulation of the immune system, and its composition affects how individuals respond to 
vaccinations (14). Sex hormones play a key role in bacterial-host interactions (15) and sex 
differences in the microbiota might therefore influence immune responses (16, 17). As 
delivery mode and feeding method strongly affect the composition of the infant microbiota 
(18), these factors might be expected to influence vaccine responses. However, in our study, 
we did not observe any significant impact of delivery mode or feeding method on vaccines 
responses. 
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Maternal antibodies may inhibit infant antibody responses to some vaccines (19). Although 
the majority of maternal antibody transfer is through the placenta, breast milk also contains 
antibodies that might interfere with immune responses. Small studies have reported that after 
routine vaccination, breast-fed infants have higher serum IgG levels to diphtheria (20), Hib 
(21, 22) and oral polio virus (OPV) (20, 23) vaccination, and higher salivary IgA levels to 
tetanus, diphtheria and OPV vaccination (20). For ORV vaccine, reduced seroconversion rates 
were observed in breast-fed infants compared with formula-fed infants (24, 25), however, this 
was not confirmed in subsequent studies (26). Infants with mixed feeding are sometimes 
classified as breast-fed and sometimes as non-breast-fed (26) and IgA levels, as well as the 
neutralising activity of IgA in breast-milk, may depend on geographic location (27). These 
factors could explain some of the inconsistency in results from different studies.  
The strengths of our study include the ability to adjust for a large number of possible 
confounding factors, the standardisation in the vaccines given and the wide range of measured 
antibody responses. The limitations of the study are the sample size and risk of type-2 error. 
Furthermore, we did not analyse antibody responses to the HepB vaccine, as this antigen was 
not included in our multiplex assay and we had insufficient sample volume for alternative 
assays. We also did not evaluate the effect of antibiotics that might have been transferred 
through breastmilk on infant vaccine responses.   
 
As most vaccines induce antibody concentrations above the protective threshold in the 
majority of infants, small differences in antibody concentrations between groups of 
individuals are unlikely to be clinically significant. However, differences in antibody 
concentrations might be relevant for the duration of protection. Nonetheless, when developing 
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new vaccines and designing vaccine schedules, recognising factors which might influence 
vaccine antibody responses, offers ways to optimise vaccine immunogenicity and efficacy. 
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Abbreviations 
BCG – Bacille Calmette-Guérin 
CI – confidence interval  
DTPa – diphtheria-tetanus-acellular pertussis vaccine  
FHA – filamentous haemagglutinin  
GMC – geometric mean concentration 
GMR – geometric mean ratio 
HepA – hepatitis A 
HepB – hepatitis B 
Hib – Haemophilus influenzae type b  
Ig – immunoglobulin  
IPV – inactivated polio vaccine  
IQR – interquartile range  
MenC – meningococcus C  
MIS BAIR – The Melbourne Infant Study: BCG for Allergy and Infection Reduction  
ORV – oral rotavirus vaccine  
PCV13 – 13-valent conjugate pneumococcal vaccine  
Pn – pneumococcus serotype 
PRN – pertactin  
PT – pertussis toxin  
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Table 1 Characteristics of study participants  
  
Total cohort 
Samples at 7 months of age 
for antibodies  
 
Samples at 13 months of age 
for persistence of antibodies  
 
Samples at 13 months of age  
for antibodies 
 to primary course of vaccines ending at 6 months of age to 12-month vaccines 
(n=365) 
n (%) or median (IQR) 
(n=91) 
n (%) or median (IQR) 
(n=307) 
n (% or IQR) 
(n=144) 
n (% or IQR) 
Sex (male) 179 (49) 43 (47) 149 (49) 71 (49) 
Gestational age (weeks) 39.3 (38.4-40.4) 39.5 (38.6-40.5) 39.3 (38.4-40.3) 39.2 (38.4-40.4) 
Birth weight (kg) 3.45 (3.13-3.76) 3.48 (3.10-3.78) 3.45 (3.13-3.76) 3.41 (3.13-3.67) 
Caesarean section 136 (37) 35 (38) 115 (37) 53 (37) 
Received formula milk in hospital in first week of life 100 (27) 25 (27) 84 (27) 37 (26) 
Still receiving breast at 1 month of age 302 (83) 80 (88) 251 (82) 119 (83) 
Still receiving breast at 6 months of age 263 (72) 71 (78) 219 (71) 107 (74) 
Antibiotics during admission for delivery     
Intrapartum antibiotics 70 (19) 21 (23) 62 (20) 32 (22) 
Antibiotics before first vaccination 30 (8) 4 (4) 29 (9) 13 (9) 
BCG-vaccinated 198 (54) 45 (49) 166 (54) 76 (53) 
Maternal dTpa vaccination in pregnancy 174 (48) 46 (51)  146 (48)  67 (47) 
Maternal influenza vaccination in pregnancy 208 (57) 55 (60) 171 (56) 84 (58) 
     
Age at routine vaccination (days)     
- 6-week vaccines 45 (43-494)1 45 (43-48)1 45 (43-49) 45 (43-48) 
- 4-month vaccines 125 (120-131) 123 (117-127) 125 (121-132) 124 (120-131) 
- 6-month vaccines 190 (184-202) 187 (181-193) 191 (185-204) 190 (185-201) 
- 12-month vaccines 376 (369-383) - - 376 (369-383) 
Interval between (days)     
- 6-month vaccines and 7-month blood sample - 28 (21-37) - - 
- 6-month vaccines and 13-month blood sample - - 209 (190-224) - 
- 12-month vaccines and 13-month blood sample - - - 28 (22-36) 
Age at blood sampling (days) - 218 (208-227) 400 (389-418) 406 (397-414) 
 
1 age for one participant not available 
 
BCG = Bacille Calmette-Guérin 
dTpa = diphtheria-tetanus-acellular pertussis vaccine 
 
 
 
  
22 
 
Table 2a Seroprotection rates at 7 and 13 months of age in female and male infants  
  Antibodies to primary course of vaccines ending at 6 months of age  
measured at 7 months of age 
Antibodies to primary course of vaccines ending at 6 months of age  
measured at 13 months of age 
Vaccine 
antigen 
Protective 
correlate 
Female 
(n=48) 
Male 
(n=43) 
Difference 
% (95% CI) 
Two-
sided 
p-value 
Female 
(n=158) 
Male 
(n=149) 
Difference 
% (95% CI) 
Two-
sided 
p-value   % (n); (95% CI) % (n); (95% CI) % (n); (95% CI) % (n); (95% CI) 
Diphtheria  0.1 IU/mL1 97.9 (47); (88.9, 99.9) 95.3 (41); (84.1, 99.4) 2.6 (-6.9, 13.7) 0.60 98.7 (156); (95.5, 99.8) 98.0 (146); (94.2, 99.6) 0.7 (-2.7, 4.6) 0.68 
Tetanus  0.1 IU/mL1 100 (48); (92.6, 100) 100 (43); (91.8, 100) 0 (-7.5, 8.3) - 100 (85); (96.8, 100)2 100 (78); (95.4, 100)2 0 (-4.3, 4.7)2 - 
PT 25 IU/mL 89.6 (43); (77.3, 96.5)  90.7 (39); (77.9, 97.4) -1.1 (-14.4, 12.7) 1  28.5 (45); (21.6, 36.2)  31.5 (47); (24.2, 39.7) -3.1 (-13.3, 7.2) 0.62 
Hib  0.15 µg/mL 66.7 (32); (51.6, 79.6) 86.0 (37); (72.1, 94.7)  -19.4 (-36.0, -1.7) 0.05 80.0 (68) (69.9, 87.9)2 73.1 (57); (61.8, 82.5)2 6.9 (-6.1, 20.1)2 0.362 
Polio type 1 0.23 IU/mL 100 (48); (92.6, 100)  100 (43); (91.8, 100) 0 (-7.5, 8.3) - 100 (158); (97.7, 100) 100 (149); (97.6, 100)  0 (-2.4, 2.5) - 
Polio type 2 0.29 IU/mL 100 (48); (92.6, 100) 100 (43); (91.8, 100)  0 (-7.5, 8.3) 1 100 (158); (97.7, 100) 99.3 (148); (96.3, 100)  0.7 (-1.7, 3.7) 0.49 
Polio type 3 0.12 IU/mL 100 (48); (92.6, 100) 100 (43); (91.8, 100) 0 (-7.5; 8.3) - 100 (158); (97.7, 100)  100 (149); (97.6, 100) 0 (-2.4, 2.5) - 
Pn 1 0.35 µg/mL 95.8 (46); (85.7, 99.5) 97.7 (42); (87.7, 99.9) -1.8 (-12.1, 8.4) 1 92.4 (146); (87.1, 96.0) 95.3 (142); (90.6, 98.1) -2.9 (-8.7, 2.7) 0.35 
Pn 3 0.35 µg/mL 97.9 (47); (88.9, 99.9) 100 (43); (91.8, 100)  -2.1 (-11.0, 6.3) 1 70.3 (111); (62.5, 77.3) 69.1 (103); (61.0, 76.4) 1.1 (-9.1, 11.4) 0.90 
Pn 4 0.35 µg/mL 66.7 (32); (51.6, 79.6)  72.1 (31); (56.3, 84.7) -5.4 (-24.0, 13.8) 0.65 24.1 (38); (17.6, 31.5) 21.5 (32); (15.2, 28.9) 2.6 (-6.9, 12.0) 0.68 
Pn 5 0.35 µg/mL 95.8 (46); (86.7, 99.5) 100 (43); (85.6, 99.5) -4.2 (-14.1, 4.3) 0.50 89.2 (141); (83.3, 93.6) 84.6 (126); (77.7, 90.0) 4.7 (-2.9, 12.5) 0.24 
Pn 6A 0.35 µg/mL 97.9 (47); (88.9, 99.9) 97.7 (42); (87.7, 99.9) 0.2 (-8.9, 10.3) 1 88.0 (139); (81.9, 92.6) 85.2 (127); (78.5, 90.5) 2.7 (-5.0, 10.6) 0.50 
Pn 6B 0.35 µg/mL 83.3 (40); (69.8, 92.5) 95.3 (41); (84.2, 99.4) -12.0 (-25.8, 1.1) 0.10 68.4 (108); (60.5, 75.5) 59.7 (89); (51.4, 67.7) 8.6 (-2.1, 19.2) 0.12 
Pn 7F 0.35 µg/mL 100 (48); (92.6, 100) 100 (43); (91.8, 100) 0 (-7.5, 8.3) - 99.4 (157); (96.5, 100) 99.3 (148); (96.3, 100) 0 (-2.9, 3.1) 1 
Pn 9V 0.35 µg/mL 97.9 (47); (88.9, 99.9) 97.7 (42); (87.7, 99.9) 0.2 (-8.9, 10.2) 1 79.1 (125); (71.9, 85.2) 72.5 (108); (64.6, 79.5) 6.6 (-3.0, 16.2) 0.18 
Pn 14 0.35 µg/mL 91.7 (44); (80.0, 97.7) 90.7 (39); (77.8, 97.4) 1.0 (-11.8, 14.6) 1 84.8 (134); (78.2, 90.0) 87.9 (131); (81.2, 92.3) -3.1 (-10.9, 4.7) 0.51 
Pn 18C 0.35 µg/mL 95.8 (46); (85.7, 99.5) 95.3 (41); (84.2, 99.4) 0.5 (-10.0, 11.9) 1 78.5 (124); (71.2, 84.6) 75.2 (112); (67.4, 81.9) 3.3 (-6.2, 12.8) 0.50 
Pn 19A 0.35 µg/mL 93.8 (45); (82.8, 98.7) 93.0 (40); (80.9, 98.5) 0.7 (-11, 13.3) 1 47.5 (75); (39.5, 55.6) 52.3 (78); (44.0, 60.6) -4.9 (-15.9, 6.3) 0.42 
Pn 19F 0.35 µg/mL 100 (46); (92.6, 100) 100 (43); (91.8, 100) 0 (-7.5; 8.3) - 98.7 (156); (95.5, 99.8) 100 (149); (97.6, 100) -1.3 (-4.5, 1.3) 0.50 
Pn 23F 0.35 µg/mL 91.7 (44); (80.0, 97.7) 95 (41); (84.2, 99.4) -3.7 (-15.7, 8.3) 0.68 62.7 (99); (54.6, 70.2) 59.7 (89); (51.4, 67.7) 2.9 (-8.0, 13.8) 0.64 
 Antibodies to 12-month vaccines  
measured 13 months of age 
Female 
(n=73) 
Male 
(n=71) 
Difference 
% (95% CI) 
Two-
sided 
p-value % (n); (95% CI) % (n); (95% CI)  
Measles 0.12 IU/mL     100 (73); (95.1, 100) 95.8 (68); (88.1, 99.1) 4.2 (-0.9, 11.7)  0.12 
Mumps 45 IU/mL     58.9 (43); (46.8, 70.3) 62.0 (44); (49.7, 73.2) -3.1 (-18.8, 12.9) 0.74 
Rubella 10 IU/mL     91.8 (67); (83.0, 96.9) 81.7 (58); (70.7, 89.9)  10.1 (-1.1, 21.8) 0.09 
MenC 2 µg/mL      100 (73); (95.1, 100)   98.6 (70); (92.4, 100) 1.4 (-3.7, 7.6) 0.49 
Hib 0.15 µg/mL     98.6 (72); (92.6, 100) 98.6 (70); (92.5, 100) 0 (-6.1, 6.4)  1 
Tetanus 0.01 IU/mL     100 (73); (95.1, 100) 100 (71); (94.3, 100)  0 (-5.0, 5.1) - 
 
1 0.01 IU/mL at 13 months of age  2 includes only participants who have not had Hib-MenC 
  
BCG = Bacille Calmette-Guérin, CI = confidence interval, Hib = H. influenzae type b, MenC = meningococcus C, Pn = pneumococcus serotype, PT = pertussis toxin 
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Table 2b Geometric mean antibody concentrations (GMCs) and geometric mean antibody ratios (GMRs) at 7 and 13 months of age in female and male infants  
 Antibodies to primary course of vaccines ending at 6 months of age  
measured at 7 months of age 
Antibodies to primary course of vaccines ending at 6 months of age  
measured at 13 months of age 
Vaccine 
antigen 
Female 
(n=48) 
Male 
(n=43) 
Unadjusted 
GMR (95% CI) 
Two-
sided 
p-
value 
Adjusted* 
GMR (95% CI) 
Two-
sided 
p-
value 
Female 
(n=158) 
Male 
(n=149) 
Unadjusted 
GMR (95% CI) 
Two-
sided 
Adjusted** 
GMR (95% CI) 
Two-
sided 
 GMC (95% CI) GMC (95% CI) GMC (95% CI) GMC (95% CI)  p-
value 
 p-
value 
Diphtheria1 0.38 (0.30, 0.48) 0.41 (0.33, 0.52) 0.92 (0.67, 1.27) 0.61 0.98 (0.72, 1.32) 0.88 0.08 (0.07, 0.09) 0.08 (0.06, 0.09) 1.05 (0.83, 1.32) 0.69 1.12 (0.91, 1.38) 0.29 
Tetanus1 0.98 (0.82, 1.18) 1.27 (1.01, 1.60) 0.77 (0.58, 1.03) 0.08 0.72 (0.54, 0.97) 0.03 0.41 (0.32, 0.52)3 0.48 (0.37, 0.61)3 0.85 (0.60, 1.22)3 0.383 0.78 (0.56, 1.10)3 0.16 
PT1 63.68 (51.21, 79.18) 77.99 (60.10, 101.22) 0.82 (0.58, 1.13) 0.23 0.85 (0.62, 1.17) 0.31 16.67 (14.26, 19.47) 18.19 (15.37, 21.54) 0.92 (0.73, 1.15) 0.45 0.98 (0.80, 1.21) 0.87 
FHA1 52.41 (42.42, 64.76) 79.28 (60.59, 103.73) 0.66 (0.47, 0.92) 0.02 0.71 (0.51, 0.98) 0.04 16.96 (14.50, 19.83) 21.17 (18.28, 24.52) 0.80 (0.65, 0.99) 0.04 0.85 (0.69, 1.04) 0.11 
PRN1  54.00 (42.26, 69.00) 68.66 (49.36, 95.50) 0.79 (0.53, 1.17) 0.24 0.80 (0.53, 1.21) 0.29 10.13 (8.39, 12.24) 14.24 (11.73, 17.28) 0.71 (0.54, 0.93) 0.02 0.73 (0.57, 0.95) 0.02 
Hib2 0.40 (0.25, 0.64) 0.68 (0.44, 1.06) 0.58 (0.30, 1.11) 0.10 0.66 (0.35, 1.26) 0.21 1.5 (0.80, 2.51)3 0.82 (0.51, 1.33)3 1.82 (0.90, 3.70)3 0.093 1.51 (0.88, 2.61)3 0.143 
Polio type 11 33.75 (24.34, 46.81) 35.59 (26.50, 47.80) 0.95 (0.61, 1.47) 0.81 1.04 (0.66, 1.65) 0.86 11.07 (9.28, 13.19) 11.32 (9.41, 13.61) 0.98 (0.76, 1.26) 0.86 1.03 (0.80, 1.32) 0.82 
Polio type 21 65.36 (49.45, 86.40) 60.43 (42.14, 86.66) 1.08 (0.69, 1.69) 0.73 1.14 (0.73, 1.78) 0.57 22.73 (18.74, 27.57) 20.46 (16.54, 25.31) 1.11 (0.83, 1.48) 0.47 1.18 (0.89, 1.56) 0.25 
Polio type 31 23.43 (17.03, 32.24) 19.41 (13.69, 27.52) 1.21 (0.76, 1.92) 0.42 1.24 (0.76, 2.01) 0.38 10.17 (8.29, 12.48) 7.71 (6.25, 9,53) 1.32 (0.98, 1.77) 0.06 1.39 (1.04, 1.84) 0.03 
Pn 12 3.97 (2.86, 5.50) 4.87 (3.70, 6.40) 0.82 (0.53, 1.25) 0.34 0.89 (0.59, 1.32) 0.55 1.18 (1.03, 1.35) 1.15 (1.00, 1.33) 1.03 (0.85, 1.25) 0.78 1.06 (0.87, 1.28) 0.58 
Pn 32 1.37 (1.15, 1.64) 1.52 (1.21, 1.90) 0.90 (0.68, 1.20) 0.48 0.91 (0.68, 1.21) 0.51 0.57 (0.50, 0.65) 0.50 (0.44, 0.57) 1.14 (0.95, 1.37)  0.15 1.17 (0.98, 1.39) 0.09 
Pn 42 0.53 (0.41, 0.69) 0.50 (0.40, 0.63) 1.06 (0.75, 1.51) 0.73 1.09 (0.77, 1.54) 0.61 0.22 (0.20, 0.25) 0.21 (0.19, 0.23) 1.05 (0.90, 1.22) 0.52 1.07 (0.92, 1.24) 0.39 
Pn 52 2.91 (2.17, 3.89) 3.46 (2.71, 4.43) 0.84 (0.57, 1.23) 0.36 0.92 (0.63, 1.33) 0.65 0.96 (0.83, 1.12) 0.88 (0.76, 1.02) 1.09 (0.89, 1.34) 0.41 1.14 (0.93, 1.39) 0.22 
Pn 6A2 4.82 (3.66, 6.34) 4.81 (3.81, 6.08) 1.00 (0.70, 1.44) 1.00 1.01 (0.72, 1.42) 0.97 1.08 (0.93, 1.25) 0.93 (0.78, 1.10) 1.16 (0.93, 1.45) 0.19 1.24 (1.01, 1.53) 0.04 
Pn 6B2 1.64 (1.04, 2.59) 2.27 (1.46, 3.54) 0.72 (0.38, 1.36) 0.31 0.72 (0.38, 1.34) 0.29 0.56 (0.47, 0.68) 0.47 (0.39, 0.57) 1.20 (0.93, 1.56) 0.17 1.25 (0.97, 1.61) 0.08 
Pn 7F2 5.72 (4.51, 7.27) 6.62 (5.31, 8.26) 0.86 (0.63, 1.20) 0.38 0.85 (0.62, 1.15) 0.29 1.93 (1.70, 2.18) 1.83 (1.61, 2.07) 1.06 (0.89, 1.26) 0.55 1.09 (0.93, 1.30) 0.29 
Pn 9V2 2.40 (1.83, 3.16) 2.52 (2.01, 3.16) 0.95 (0.67, 1.36) 0.79 0.99 (0.71, 1.37) 0.94 0.63 (0.55, 0.72) 0.57 (0.49, 0.65) 1.12 (0.92, 1.36) 0.26 1.16 (0.96, 1.40) 0.12 
Pn 142 2.54 (1.82, 3.56) 2.81 (1.86, 4.26) 0.90 (0.54, 1.53) 0.70 0.88 (0.52, 1.51) 0.65 1.09 (0.93, 1.29) 1.00 (0.85, 1.18) 1.09 (0.87, 1.37) 0.46 1.13 (0.90, 1.43) 0.28 
Pn 18C2 2.68 (1.96, 3.65) 3.27 (2.59, 4.13) 0.82 (0.55, 1.21) 0.31 0.83 (0.56, 1.22) 0.35 0.69 (0.60, 0.78) 0.62 (0.54, 0.71) 1.11 (0.92, 1.34) 0.28 1.16 (0.97, 1.40) 0.10 
Pn 19A2 1.77 (1.34, 2.34) 1.67 (1.25, 2.22) 1.06 (0.71, 1.58) 0.77 1.14 (0.76, 1.69) 0.52 0.48 (0.38, 0.60) 0.45 (0.37, 0.54) 1.06 (0.79, 1.42) 0.70 1.10 (0.83, 1.47) 0.51 
Pn 19F2 10.20 (7.71, 13.50) 13.22 (10.40, 16.79) 0.77 (0.53, 1.11) 0.17 0.80 (0.56, 1.15) 0.22 3.21 (2.72, 3.79) 3.00 (2.52, 3.58) 1.07 (0.84, 1.36) 0.58 1.11 (0.87, 1.40) 0.40 
Pn 23F2 2.27 (1.64, 3.15) 2.41 (1.69, 3.44) 0.94 (0.58, 1.52) 0.81 0.96 (0.60, 1.52) 0.85 0.63 (0.52, 0.77) 0.50 (0.41, 0.61) 1.26 (0.96, 1.66) 0.10 1.27 (0.97, 1.68) 0.08 
 Antibodies to 12-month vaccines  
measured 13 months of age 
Female 
(n=73) 
Male 
(n=71) 
Unadjusted 
GMR (95% CI) 
p-
value 
Adjusted* 
GMR (95% CI) 
p-
value 
GMC (95% CI) GMC (95% CI)     
Measles1                                                                      3.66 (3.05-4.40) 2.49 (1.83-3.41) 1.47 (1.03, 2.10) 0.03 1.45 (1.01, 2.09) 0.04 
Mumps1       58.93 (43.31, 80.20) 57.40 (42.07, 78.32) 1.03 (0.67, 1.58) 0.90 0.94 (0.65, 1.35) 0.73 
Rubella1       60.78 (44.83, 82.40) 45.04 (31.74, 63.92) 1.35 (0.85, 2.14) 0.20 1.25 (0.86, 1.81) 0.25 
MenC2       19.47 (16.47, 23.00) 15.89 (12.84, 19.66) 1.23 (0.94, 1.60) 0.14 1.27 (0.97, 1.65) 0.08 
Hib2       18.21 (13.08, 25.35) 13.01 (8.74, 19.38) 1.40 (0.84, 2.33) 0.20 1.53 (0.93, 2.53) 0.10 
Tetanus1       0.83 (0.64, 1.08) 1.19 (0.88, 1.60) 0.70 (0.47, 1.04) 0.07 0.73 (0.49, 1.08) 0.12 
 
1 IU/ml  2 µg/ml  3 includes only participants who have not had Hib-MenC  
 
BCG = Bacille Calmette-Guérin, CI = confidence interval, GMC = geometric mean antibody concentration, GMR = geometric mean antibody ratio, FHA = filamentous haemagglutinin, Hib = H. influenzae type b, MMR = 
measles-mumps-rubella, MenC = meningococcus C, Pn = pneumococcus serotype, PRN = pertactin, PT = pertussis toxin  
 
*adjusted for maternal dTpa (diphtheria-tetanus-aceulluar pertussis) and trivalent influenza vaccine during pregnancy, gestational age, BCG vaccination status, age at first DTPa-HepB-IPV-Hib / PCV13 vaccination, age 
at sampling and time between vaccination and sampling using multiple linear regression 
 
**adjusted for maternal dTpa (diphtheria-tetanus-aceulluar pertussis) and trivalent influenza vaccine during pregnancy, gestational age, BCG and MMR vaccination status, age at first DTPa-HepB-IPV-Hib / PCV13 
vaccination, age at sampling and time between vaccination and sampling using multiple linear regression
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Figure 1 Selection of participants  
 
       
   * 33 participants had their blood analysed at both 7 and 13 months of age
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Figure 2 Seroprotection rates and geometric mean antibody concentrations (GMCs) in female and male infants 
 
 
 
